This first report that G-CSF was associated with increased inflammation was followed by a case report describing severe disease exacerbation with EDSS progression and several new brain lesions following G-CSF administration to a 31-year-old woman with previously stable RRMS, following treatment for breast cancer with chemotherapy and subcutaneous G-CSF [57]. The gene discussed is CSF3; the disease is breast cancer.